Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Traws Pharma, Inc.
13G/A
Amendment 4
TRAW · 68232V884
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 0% | ||||
| Squadron Capital Management LLC | 0% | ||||
| Matthew Sesterhenn | 0% | ||||
| William Blank | 0% | ||||
|
Relmada Therapeutics, Inc.
13G/A
Amendment 3
RLMD · 75955J402
|
7.0% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 7.0% | ||||
| Squadron Capital Management LLC | 7.0% | ||||
| Matthew Sesterhenn | 7.0% | ||||
| William Blank | 7.0% | ||||
|
NextCure, Inc.
13G/A
Amendment 2
NXTC · 65343E207
|
1.6% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 1.6% | ||||
| Squadron Capital Management LLC | 1.6% | ||||
| Matthew Sesterhenn | 1.6% | ||||
| William Blank | 1.6% | ||||
|
Lipocine Inc.
13G/A
Amendment 3
LPCN · 53630X203
|
9.8% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 9.8% | ||||
| Squadron Capital Management LLC | 9.8% | ||||
| Matthew Sesterhenn | 9.8% | ||||
| William Blank | 9.8% | ||||
|
C4 Therapeutics, Inc.
13G/A
Amendment 1
CCCC · 12529R107
|
6.9% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 6.9% | ||||
| Squadron Capital Management LLC | 6.9% | ||||
| Matthew Sesterhenn | 6.9% | ||||
| William Blank | 6.9% | ||||
|
Quince Therapeutics, Inc.
13G
QNCX · 22053A305
|
5.6% |
8/4/2026
Event 7/28/2026
|
|||
| Squadron Master Fund LP | 5.6% | ||||
| Squadron Capital Management LLC | 5.6% | ||||
| Matthew Sesterhenn | 5.6% | ||||
| William Blank | 5.6% | ||||
|
InMed Pharmaceuticals Inc.
13G
INM · 457637700
|
9.8% |
5/27/2026
Event 5/19/2026
|
|||
| Squadron Master Fund LP | 9.8% | ||||
| Squadron Capital Management LLC | 9.8% | ||||
| Matthew Sesterhenn | 9.8% | ||||
| William Blank | 9.8% | ||||
|
C4 Therapeutics, Inc.
13G
CCCC · 12529R107
|
5.0% |
5/19/2026
Event 5/12/2026
|
|||
| Squadron Master Fund LP | 5.0% | ||||
| Squadron Capital Management LLC | 5.0% | ||||
| Matthew Sesterhenn | 5.0% | ||||
| William Blank | 5.0% | ||||
|
Spruce Biosciences, Inc.
13G/A
Amendment 2
SPRB · 85209E208
|
0.9% |
5/15/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 0.9% | ||||
| Squadron Capital Management LLC | 0.9% | ||||
| Matthew Sesterhenn | 0.9% | ||||
| William Blank | 0.9% | ||||
|
Lipocine Inc.
13G/A
Amendment 2
LPCN · 53630X203
|
6.2% |
5/15/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 6.2% | ||||
| Squadron Capital Management LLC | 6.2% | ||||
| Matthew Sesterhenn | 6.2% | ||||
| William Blank | 6.2% | ||||
|
Traws Pharma, Inc.
13G/A
Amendment 3
TRAW · 68232V884
|
6.4% |
5/15/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 6.4% | ||||
| Squadron Capital Management LLC | 6.4% | ||||
| Matthew Sesterhenn | 6.4% | ||||
| William Blank | 6.4% | ||||
|
Scynexis Inc
13G
SCYX · 811292200
|
9.6% |
4/8/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 9.6% | ||||
| Squadron Capital Management LLC | 9.6% | ||||
| Matthew Sesterhenn | 9.6% | ||||
| William Blank | 9.6% | ||||
|
Aprea Therapeutics, Inc.
13G
APRE · 03836J102
|
9.9% |
4/7/2026
Event 3/30/2026
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| William Blank | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
|
Zentalis Pharmaceuticals, Inc.
13G
ZNTL · 98943L107
|
5.1% |
3/3/2026
Event 2/24/2026
|
|||
| Squadron Master Fund LP | 5.1% | ||||
| Squadron Capital Management LLC | 5.1% | ||||
| Matthew Sesterhenn | 5.1% | ||||
| William Blank | 5.1% | ||||
|
Traws Pharma, Inc.
13G/A
Amendment 2
TRAW · 68232V884
|
8.9% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 8.9% | ||||
| Squadron Capital Management LLC | 8.9% | ||||
| Matthew Sesterhenn | 8.9% | ||||
| William Blank | 8.9% | ||||
|
Spruce Biosciences, Inc.
13G/A
Amendment 1
SPRB · 85209E208
|
6.5% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 6.5% | ||||
| Squadron Capital Management LLC | 6.5% | ||||
| Matthew Sesterhenn | 6.5% | ||||
| William Blank | 6.5% | ||||
|
Relmada Therapeutics, Inc.
13G/A
Amendment 2
RLMD · 75955J402
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| William Blank | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 1
PALI · 696389402
|
3.0% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 3.0% | ||||
| Squadron Capital Management LLC | 3.0% | ||||
| Matthew Sesterhenn | 3.0% | ||||
| William Blank | 3.0% | ||||
|
NextCure, Inc.
13G/A
Amendment 1
NXTC · 65343E207
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
| William Blank | 9.9% | ||||
|
Lipocine Inc.
13G/A
Amendment 1
LPCN · 53630X203
|
9.5% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 9.5% | ||||
| Squadron Capital Management LLC | 9.5% | ||||
| Matthew Sesterhenn | 9.5% | ||||
| William Blank | 9.5% | ||||
|
Pasithea Therapeutics Corp.
13G/A
Amendment 1
KTTA · 70261F202
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
| William Blank | 9.9% | ||||
|
Lipocine Inc.
13G
LPCN · 53630X203
|
9.0% |
12/23/2025
Event 12/18/2025
|
|||
| Squadron Master Fund LP | 8.0% | ||||
| Squadron Capital Management LLC | 9.0% | ||||
| Matthew Sesterhenn | 9.0% | ||||
| William Blank | 9.0% | ||||
|
Pasithea Therapeutics Corp.
13G
KTTA · 70261F202
|
9.9% |
12/5/2025
Event 11/28/2025
|
|||
| Squadron Master Fund LP | 7.3% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
| William Blank | 9.9% | ||||
|
Traws Pharma, Inc.
13G/A
Amendment 1
TRAW · 68232V884
|
8.4% |
11/14/2025
Event 9/30/2025
|
|||
| Squadron Master Fund LP | 7.4% | ||||
| Squadron Capital Management LLC | 8.4% | ||||
| Matthew Sesterhenn | 8.4% | ||||
| William Blank | 8.4% | ||||
|
NextCure, Inc.
13G
NXTC · 65343E207
|
6.5% |
10/24/2025
Event 10/21/2025
|
|||
| Squadron Master Fund LP | 5.8% | ||||
| Squadron Capital Management LLC | 6.5% | ||||
| Matthew Sesterhenn | 6.5% | ||||
| William Blank | 6.5% | ||||
|
Spruce Biosciences, Inc.
13G
SPRB · 85209E208
|
6.6% |
10/15/2025
Event 10/8/2025
|
|||
| Squadron Master Fund LP | 5.8% | ||||
| Squadron Capital Management LLC | 6.6% | ||||
| Matthew Sesterhenn | 6.6% | ||||
| William Blank | 6.6% | ||||
|
Palisade Bio, Inc.
13G
PALI · 696389402
|
8.5% |
10/8/2025
Event 10/1/2025
|
|||
| Squadron Master Fund LP | 7.6% | ||||
| Squadron Capital Management LLC | 8.5% | ||||
| Matthew Sesterhenn | 8.5% | ||||
| William Blank | 8.5% | ||||
|
Traws Pharma, Inc.
13G
TRAW · 68232V884
|
6.0% |
9/19/2025
Event 9/12/2025
|
|||
| Squadron Master Fund LP | 5.3% | ||||
| Squadron Capital Management LLC | 6.0% | ||||
| Matthew Sesterhenn | 6.0% | ||||
| William Blank | 6.0% | ||||
|
Relmada Therapeutics, Inc.
13G/A
Amendment 1
RLMD · 75955J402
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Squadron Master Fund LP | 8.8% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| William Blank | 9.9% | ||||
|
Relmada Therapeutics, Inc.
13G
RLMD · 75955J402
|
6.2% |
5/1/2025
Event 4/24/2025
|
|||
| Squadron Master Fund LP | 5.5% | ||||
| Squadron Capital Management LLC | 6.2% | ||||
| William Blank | 6.2% | ||||